Erythromycin 500 mg Tablets Recalled for Impurity Above Limits
Zydus Pharmaceuticals is recalling erythromycin 500 mg tablets nationwide due to the presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit, resulting from manufacturing deviations.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is FDA Class II with a chemical impurity (N-Nitroso-Desmethyl-Erythromycin) above acceptable limits, which carries potential for harm. Class II recalls meet the Severe threshold per the rubric.
Plain-English summary
Zydus Pharmaceuticals (USA) Inc. is recalling erythromycin tablets, USP, 500 mg, 30 tablets per bottle, distributed nationwide. The recall was initiated because the tablets contain N-Nitroso-Desmethyl-Erythromycin at levels above the recommended acceptable intake limit due to current good manufacturing practice (CGMP) deviations.
The affected product was manufactured by Zydus Lifesciences Ltd. in Ahmedabad, India, and distributed by Zydus Pharmaceuticals (USA) Inc. in Pennington, New Jersey. The recalled lot numbers are M411147 (expiring 08/2026), M502100 (expiring 01/2027), and M502099 (expiring 01/2027), affecting approximately 10,992 bottles.
Patients currently taking erythromycin from the recalled lots should contact their healthcare provider or pharmacist for guidance. Consumers should not discontinue use of erythromycin without consulting their healthcare provider, as abrupt discontinuation may result in treatment failure.
The recalled product
- Product
- ERYTHROMYCIN (ERYTHROMYCIN)
- Brand
- ERYTHROMYCIN
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Category
- Drug — Oral Tablet
- Affected units
- 10,992
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lots: a) M411147
- Expires: 08/2026
- M502100
- M502099
- Expires: 01/2027.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Zydus Pharmaceuticals (USA) Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · ERYTHROMYCIN
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
Same manufacturer · Zydus Pharmaceuticals (USA) Inc
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- HighIcosapent ethyl capsules recalled after active ingredient oxidized inside capsule
FDA (Drugs) · 2026-03-18
- HighIcosapent ethyl capsules recalled as subpotent after capsule contents leaked
FDA (Drugs) · 2026-01-28
- LowTrazodone tablets recalled after complaints of a dent on the tablet surface
FDA (Drugs) · 2026-01-07
- ModerateBromocriptine capsules recalled after an out of specification impurity result
FDA (Drugs) · 2025-11-26
Same hazard · chemical impurity
See all →- HighDuloxetine Delayed-Release Capsules Recalled for Manufacturing Impurity Above Safe Limits
FDA (Drugs) · 2025-01-15
- HighDuloxetine antidepressant recall for chemical impurity above FDA limit
FDA (Drugs) · 2025-01-01
- HighMorphine Sulfate Extended-Release Tablets Recalled for Impurities and Degradation
FDA (Drugs) · 2024-11-13
- HighCinacalcet Tablets Recalled Due to Nitrosamine Impurity
FDA (Drugs) · 2024-11-06
- HighFDA Recalls Dexamethasone Sodium Phosphate Injection Due to Impurity Specification Failure
FDA (Drugs) · 2024-06-26